Authors: Piero Sangaletti Edge-Institute Austria at ER-System Mechatronics, Golling, Austria, Advisory Board of Concerned Scientists, Tampa, Florida USA, Antonietta GattiCofounder and Principal Investigator of Nanodiagnostics, SRL (Società a Responsabilità Limitata), Italy. Clemens Arvay Independent scientist and textbook author in Health Ecology, Vienna and Graz,

Abstract

The engineered spike protein of SARS-COV-2, and the corresponding infectious disease COVID-19 attributed to it, hold in their grip a large portion of humanity. The global race for a counter strategy quickly turned into a search for a vaccine as the preferred means to contain the virus. An unusually rapid development of different and completely new classes of experimental therapies that would widely be referred to as “vaccines” raised questions about safety, especially with regard to emergency use approval (EUA) being granted with unprecedented urgency and hardly any critical scrutiny. At present, independent researchers, even some former proponents and insiders, of the currently ongoing global experiment represented as a “vaccination” campaign point primarily to the lack of public safety studies based on empirical datasets that should be obtainable for the tens of millions, even hundreds of millions, of doses of mRNA and DNA vector therapeutics being distributed as “vaccines”. Studies regarding efficacy and “side effects” (sometimes fatalities or permanent iatrogenic injuries) of these experimental therapies have been by-passed in favor of short-term field data from real patients which inevitably raises scientific and ethical questions particularly in view of the fact that the persons and entities responsible for public safety hold deep financial and other vested interests in speeding along the distribution of the experimental pharmaceutical products. The lack of an open discussion about the experimental therapies for COVID-19 now being applied across all age groups, even children hardly impacted by COVID-19, is worrying. The core principle of open debate without pre-conceptions or vested interests in outcomes has been and continues to be utterly ignored. We hope to engage scientific discussion with the hope of helping decision-makers, the general public, and the media alike to consider the subject-matter of what is at stake in a context of reason rather than panic.

References

Adiguzel, Y., (2021). Molecular mimicry between SARS-CoV-2 and human proteins. Autoimmunity Reviews, 20(4), 102791. https://doi.org/10.1016/j.autrev.2021.102791

Agmon-Levin, N., Paz, Z., Israeli, E., & Shoenfeld Y. (2009) Vaccines and autoimmunity. Nat Rev Rheumatol, 5(11):648-52. https://doi.org/10.1038/nrrheum.2009.196

Alwan, N.A., Burgess, R.A., Ashworth, S., Beale, R., Bhadelia, N., Bogaert, D., Dowd, J., Eckerle, I., Goldman, L.R., Greenhalgh, T., Gurdasani, D., Hamdy, A., Hanage, W.P., Hodcroft, E.B., Hyde, Z., Kellam, P., Kelly-Irving, M., Krammer, F., Lipsitch, M., McNally, A., McKee, M., Nouri, A., Pimenta, D., Priesemann, V., Rutter, H., Silver, J., Sridhar, D., Swanton, C., Walensky, R.P., Yamey, G., & Ziauddeen, H. (2020). Scientific consensus on the COVID-19 pandemic: we need to act now. Lancet 396(10260): e71-e72. https://doi.org/10.1016/S0140-6736(20)32153-X. The corresponding “John Snow Memorandum” is available online https://www.johnsnowmemo.com/john-snow-memo.html (accessed: Feb. 2021)

Andeweg, S.P., Vennema, H., Veldhuijzen, I.K., Smorenburg, N., Schmitz, D., Zwagemaker, F., SeqNeth, Molecular surveillance group, RIVM COVID-19 Molecular epidemiology group, van Gageldonk-Lafeber, A.B., Chantal, S.H., Reusken REM, Knol, M.J., & Eggink, D. (2021). Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals. medRxiv: 244530109. https://doi.org/10.1101/2021.11.24.21266735

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A., Simons, D., Blomquist, P.B., Dabrera, G., Myers, R., Ladhani, S.N., Amirthalingam, G., Gharbia, S., Barrett, J.C., Elson, R., Ferguson, N., Zambon, M., Campbell, C.N.J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., & Lopez Bernal, J. (2021). Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv, 2021.12.14.21267615. https://doi.org/10.1101/2021.12.14.21267615

Aubrit, F., Perugi, F., Léon, A., Guéhenneux, F., Champion-Arnaud, P., Lahmar, M., & Schwamborn K (2015). Cell substrates for the production of viral vaccines. Vaccine, 33(44): 5905-5912. https://doi.org/10.1016/j.vaccine.2015.06.110

Arvay, C. (2020). Genetische Impfstoffe gegen COVID-19: Hoffnung oder Risiko? [Genetic Vaccines Against COVID-19: Hope Or Risk?] Schweiz Ärztezeitung, 101(2728): 862-864. https://doi.org/10.4414/saez.2020.18982

Avci, E., & Abasiyanik, F. (2021). Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up? J Autoimmun 125: 102745. https://doi.org/10.1016/j.jaut.2021.102745

Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A.M., Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther, 25(6):1316-1327. https://doi.org/10.1016/j.ymthe.2017.03.035

Baum, C., Kustikova, O., Modlich, U., Li, Z.X., & Fehse, B. (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther , 17(3): 253-263. https://doi.org/10.1089/hum.2006.17.253

Birnhack, M. (2021). Who Controls COVID-Related Medical Data? Copyright and Personal Data. IIC 52: 821–824. Doi: 10.1007/s40319-021-01067-5; related source file: https://govextra.gov.il/media/30806/11221-moh-pfizer-collaboration-agreement-redacted.pdf (accessed: Feb. 2021)

BL, (2020). Dr. Kary Mullis—Inventor of PCR. Benevolent Lite. https://www.youtube.com/watch?v=7j8STZQWFi4 (accessed: Dec. 2021)

Blankenhorn, D. (2021). Novavax Stock Needs a Longer Pandemic as Investor Patience Wears Thin. Investor Place (accessed: Sept. 2021): https://markets.businessinsider.com/news/stocks/novavax-stock-needs-a-longer-pandemic-as-investor-patience-wears-thin-1030833455

Blaylock, R.L. (2021). Excitotoxicity (immunoexcitotoxicity) as a critical component of the cytokine storm reaction in pulmonary viral infections, including SARS-CoV-2. International Journal of Vaccine Theory, Practice, and Research, 1(2), 223–242. https://ijvtpr.com/index.php/IJVTPR/article/view/14

Bock, J. (2021). Vaccinating people who have had COVID-19: why doesn’t natural immunity count in the US? BMJ, 374: n2101. https://doi.org/10.1136/bmj.n2101

BN, (2019a). Vaccino antiinfluenzale: a Bergamo ordinate 185 000 dosi. Bergamo News. https://www.bergamonews.it/2019/10/21/vaccinazione-antinfluenzale-a-bergamo-ordinate-185-000-dosi-di-vaccino/332164/?fbclid=IwAR1glyhj6RQOqOp8YbBf5oLMrknl8P4DyQ-k_GsVicLA-vWuTFwiITSUnzM (accessed: May 2020)

BN, (2019b). Emergenza Meningite, Vaccinate 34mila persone tra Brescia e Bergamo. Bergamo News. https://www.bsnews.it/2020/01/18/meningite-vaccinate-34mila-persone-tra-brescia-e-bergamo/?fbclid=IwAR1bsaQy4Ppd21k4WLPkYYMnpiBY5tEtdk5gEH25rZfrGjTDyI_RnxNytNU (accessed: May 2020)

Bresalier, R.S., Sandler, R.S., Quan, H., Bolognese, J.A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M.A., & Baron, J.A. (2005). Adenomatous polyp prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352(11): 1092-1102. https://doi.org/10.1056/NEJMoa050493

Broudy, D. (2021). Vaccine development and social control: A psychopathology of impaired reasoning in the global push for mass compliance. International Journal of Vaccine Theory, Practice, and Research, 2(1), 93–124. https://ijvtpr.com/index.php/IJVTPR/article/view/23

Broudy, D., & Arakaki, M. (2020). Who wants to be a slave? The technocratic convergence of humans and data. Frontiers in Communication, 5. https://doi.org/10.3389/fcomm.2020.00037

Broudy, D., & Hoop, D. (2021). Messianic mad men, medicine, and the media war on empirical reality: Discourse analysis of mainstream COVID-19 propaganda. International Journal of Vaccine Theory, Practice, and Research, 2(1), 1–24. https://ijvtpr.com/index.php/IJVTPR/article/view/22

Broudy, D., & Kyrie, V. (2021). Syllogistic reasoning demystifies evidence of COVID-19 vaccine constituents. International Journal of Vaccine Theory, Practice, and Research, 2(1), 149–172. https://ijvtpr.com/index.php/IJVTPR/article/view/23

Bruno, R., McCullough, P.A.I., Villa. T,F., Henrion-Caude A, García-Gasca, T., Zaitzeva, G.P., Priester, S., Albarracín, M.J.M., Sousa-Escandon, A., Mirones, F.L., Payeras-Cifre, B., Zaragoza-Velilla, A., Borini, L.M., Mas, M., Salazar, R., Schinder, E., Yahbes, E.A., Witt, M., Salmeron, M., Fernández, P., Marchesini, M.M., Kajihara, A.J., De La Riva, M.V., Chimeno, P.J., Grellet, P.A., Lisdero, M., Mas, P., Baudo, A.J.G., Retamoza, E., Botta, O., Brandolino, C.C., Sciuto, J., Avivar, M.C., Castillo, M., Villarroel, P., Poblete-Rojas, E.P., Aguayo, B., Macías-Flores, D.I., Rossell, J.V., Sarmiento, J.C., Andrade-Sotomayor, V., Stokes-Baltazar, W.R., Cedeño-Escobar, V., Arrúa, U., Farina del Río, A., Campos-Esquivel, T., Callisperis, P., Barrientos, M.E., Fiala, C., & Acevedo-Whitehouse, K. (2021). SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers. Authorea, preprint. https://doi.org/10.22541/au.162136772.22862058/v1

Buchbinder, S.P., McElrath, M.J., Dieffenbach, C., & Corey, L. (2020). Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet, 396(10260):e68-e69. https://doi.org/10.1016/S0140-6736(20)32156-5

Buda, S., Preuss, U., Wedde, M., & Duerrwald, R. (2019). Effectiveness of vaccination against seasonal influenza — vaccine effectiveness (Wirksamkeit der Impfung gegen saisonale Influenza – Impfeffektivität), In: Report on the Epidemiology of Influenza in Germany, Season 2018/19 (Bericht zur Epidemiologie der Influenza in Deutschland, Saison 2018/19), Robert Koch-Institut, Berlin (FRG). https://doi.org/10.25646/6232; https://influenza.rki.de/Saisonberichte/2018.pdf (accessed: July 2020)

Burrell, S.A.M., & Exley, C. (2010). There is (still) too much aluminium in infant formulas. BMC Pediatrics, 10, 63. https://doi.org/10.1186/1471-2431-10-63

Burrell, C.J., Howard, C.R., & Murphy, F.A. (2016) Fenner and White’s Medical Virology, 5th ed. Academic Press Elsevier Publisher, San Diego (CA). ISBN 978-0-12-375156-0

Butnaru, D., & Shoenfeld, Y. (2015). Adjuvants and lymphoma risk as part of the ASIA spectrum. Immunologic Research, 61(1–2), 79–89. https://doi.org/10.1007/s12026-014-8622-0

Cabanillas, B., Akdis, C., & Novak, N. (2020). Allergic reactions to the first COVID‐19 vaccine: a potential role of Polyethylene glycol? Allergy 14711. https://doi.org/10.1111/all.14711

Cao, W., He, L., Cao, W., Huang, X., Jia, K., & Dai, J. (2020). Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Acta Biomater, 112:14-28. https://doi.org/10.1016/j.actbio.2020.06.009

Cappello, F., Gammazza, A.M., Dieli, F., de Macario E.C., Macario, A.J. (2020). Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis. J Clin Med, 9(7): 2038. https://doi.org/10.3390/jcm9072038

CDC, (2020). Weekly Updates by Select Demographic and Geographic Characteristics – Provisional Death Counts for Coronavirus Disease 2019 (COVID-19). Center for Disease Control. Centers for Disease and Control Prevention. https://www.cdc.gov/nchs/nvss/vsrr/COVID_weekly/index.htm (accessed: June 2020).

CDC, (2021a). Emerging SARS-CoV-2 Variants” Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html (accessed: Jan. 2020)

CDC, (2021b). Development of Antibodies and Immunity. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html (accessed: Sept. 2021)

CDC, (2021c). Interim Guidelines for COVID-19 Antibody Testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html (accessed: Sept. 2021)

Chang, M.C., Hur, J., & Park, D. (2020). Interpreting the COVID-19 Test Results: A Guide for Physiatrists. Am J Phys Med Rehabil, 99(7): 583-585. https://doi.org/10.1097/PHM.0000000000001471

Chau, N.V.V., Ngoc, N.M., Nguyet, L.A., Quang, V.M., Ny, N.T.H., Khoa, D.B., Phong, N.T., Toan, L.M., Hong, N.T.T., Tuyen, N.T.K., Phat, V.V., Nhu, L.N.T., Truc, N.H.T., That, B.T.T., Thao, H.P., Thao, T.N.P., Vuong, V.T., Tam, T.T.T., Tai, N.T., Bao, H.T., Nhung, H.T.K., Minh, N.T.N., Tien, N.T.M., Huy, N.C., Choisy, M., Man, D.N.H., Ty, D.T.B., Anh, N.T., Uyen, L.T.T., Tu, T.N.H., Yen, L.M., Dung, N.T., Hung, L.M., Truong, N.T., Thanh, T.T., Thwaites, G., & Tan, L.V. (2021). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. E-Clinical Medicine, 41: 101143. https://doi.org/10.1016/j.eclinm.2021.101143

CHD (2021). Ending childhood health epidemics. Children’s Health Defense. https://childrenshealthdefense.org/ (accessed: Dec. 2021)

Chen YY, Syed AM, MacMillan P, Rocheleau JV, Chan WCW (2020) Flow rate affects nanoparticle uptake into endothelial cells. Adv Mater, 32(24): e1906274. https://doi.org/10.1002/adma.201906274

Chen, Y., Xu, Z., Wang, P., Li, X.M., Shuai, Z.W., Ye, D.Q., & Pan, H.F. (2021) New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology, [ahead of print]. https://doi.org/10.1111/imm.13443

Chung, Y.H., Beiss, V., Fiering, S.N., & Steinmetz, N.F. (2020). COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano, 14(10), 12522–12537. https://doi.org/10.1021/acsnano.0c07197 Full text PDF 2021 available at https://pubs.acs.org/doi/pdf/10.1021/acsnano.0c07197

Cerpa-Cruz, S., Paredes-Casillas, P., Landeros-Navarro, E., Bernard-Medina, A.G., Martínez-Bonilla, G., & Gutiérrez-Ureña, S. (2013). Adverse events following immunization with vaccines containing adjuvants. Immunol Res,. 56(2-3): 299-303. https://doi.org/10.1007/s12026-013-8400-4